The EXEL chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the EXEL chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The EXEL stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View EXEL Detailed Price Forecast - CNN Money||View EXEL Detailed Summary - Google Finance|
|View EXEL Detailed Summary - Yahoo! Finance||View EXEL Stock Research & Analysis - Zacks.com|
|View EXEL Trends & Analysis - Trade-Ideas||View EXEL Major Holders - Barrons|
|View EXEL Call Transcripts - NASDAQ||View EXEL Breaking News & Analysis - Seeking Alpha|
|View EXEL Annual Report - CompanySpotlight.com||View EXEL OTC Short Report - OTCShortReport.com|
|View EXEL Fundamentals - TradeKing||View EXEL SEC Filings - Bar Chart|
|View Historical Prices for EXEL - The WSJ||View Performance/Total Return for EXEL - Morningstar|
|View the Analyst Estimates for EXEL - MarketWatch||View the Earnings History for EXEL - CNBC|
|View the EXEL Earnings - StockMarketWatch||View EXEL Buy or Sell Recommendations - MacroAxis|
|View the EXEL Bullish Patterns - American Bulls||View EXEL Short Pain Metrics - ShortPainBot.com|
|View EXEL Stock Mentions - StockTwits||View EXEL Stock Mentions - PennyStockTweets|
|View EXEL Stock Mentions - Twitter||View EXEL Investment Forum News - Investor Hub|
|View EXEL Stock Mentions - Yahoo! Message Board||View EXEL Stock Mentions - Seeking Alpha|
|View Insider Transactions for EXEL - SECform4.com||View Insider Transactions for EXEL - Insider Cow|
|View EXEL Major Holdings Summary - CNBC||View Insider Disclosure for EXEL - OTC Markets|
|View Insider Transactions for EXEL - Yahoo! Finance||View Institutional Holdings for EXEL - NASDAQ|
|View EXEL Stock Insight & Charts - FinViz.com||View EXEL Investment Charts - StockCharts.com|
|View EXEL Stock Overview & Charts - BarChart||View EXEL User Generated Charts - Trading View|
Exelixis to Release Second Quarter 2018 Financial Results on Wednesday, August 1, 2018
Posted on Tuesday July 17, 2018
Exelixis, Inc. (EXEL) announced today that its second quarter 2018 financial results will be released on Wednesday, August 1, 2018 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading.
See what the IHS Markit Score report has to say about Exelixis Inc.
Posted on Monday July 16, 2018
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on July 12. Over the last one-month, outflows of investor capital in ETFs holding EXEL totaled $22 million.
Top 5 Biotech Stocks for 2018
Posted on Wednesday July 11, 2018
Biotech is a notoriously risky business. Many biotechnology products do not produce the desired results consistently, while others fail to gain acceptance in the marketplace. Of course, when a biotech product succeeds, investors can make a lot of money.
Why Analysts are Mostly Positive On Acceleron Pharma
Posted on Monday July 09, 2018
After Acceleron’s and Celgene’s (CELG) June 28 announcement of the Phase 3 MEDALIST trial results, Acceleron stock started rising, recording ~42.79% growth on June 29 to close at $48.52. Celgene and Acceleron Pharma conducted the MEDALIST trial to evaluate the safety and efficacy of luspatercept for the treatment of individuals with myelodysplastic syndrome and chronic anemia who are not eligible or are intolerant to erythropoietin-stimulating agents.